Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Biotecnología

Dr. Stephen  LaMond M.B.A., Pharm.D., PharmD MBA

Interim Chief Executive Officer, Chief Operating Officer, Sec. & Director

Mr. Timothy M. Cunningham CPA, CPA, M.B.A.

Acting Chief Financial Officer

Dr. Hoyoung  Huh M.D., Ph.D.

Executive Chairman (Leave of Absence)

Dr. Satyajit  Mitra Ph.D.

Head of Oncology & Executive Director

Mr. Timothy M. Cunningham CPA, M.B.A.

Head of Oncology  & Executive Director

Mr. Stephen  LaMond PharmD MBA

Chief Operating Officer, Sec. & Director

Chief Executive Officer & Exec. Chairman

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
Exopharm Limited	0M
Yunnan Botanee Bio-Technology Group Co.LTD	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M

Peak Bio, Inc.

Peak Bio, Inc. Lista de competidores

Principales competidores